SCHEMBL1924136

SCHEMBL1924136

Cc1cc(-c2cnn3c(C(F)(F)F)cc(-c4ccc(C(F)(F)F)c(C(F)(F)F)c4)nc23)ccn1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.56
POLB P06746 1/20 0.52
HSD17B10 Q99714 7/20 0.50
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
KDM4E B2RXH2 6/20 0.46
LMNA P02545 1/20 0.42
HPGD P15428 6/20 0.41
ALDH1A1 P00352 5/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
TSHR P16473 2/20 0.41
CASP1 P29466 2/20 0.41
MAPK1 P28482 2/20 0.41
HTT P42858 1/20 0.41
GRM2 Q14416 2/20 0.40
CASP7 P55210 1/20 0.40
S1PR1 P21453 1/20 0.40
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1924864 0.93 MAPT (0.55) MAPTPOLBHSD17B10MEN1KMT2A
SCHEMBL1924676 0.92 MAPT (0.54) MAPTPOLBHSD17B10MEN1KMT2A
SCHEMBL1924974 0.88 MAPT (0.51) MAPTPOLBHSD17B10MEN1KMT2A
SCHEMBL1924758 0.88 MAPT (0.51) MAPTPOLBHSD17B10MEN1KMT2A
SCHEMBL1924890 0.88 MAPT (0.50) MAPTPOLBHSD17B10MEN1KMT2A
SCHEMBL1926258 0.88 GRM2 (0.51) MAPTPOLBHSD17B10MEN1KMT2A
SCHEMBL1923994 0.87 MAPT (0.61) MAPTPOLBHSD17B10MEN1KMT2A
SCHEMBL1924886 0.87 MAPT (0.55) MAPTPOLBHSD17B10MEN1KMT2A
SCHEMBL1924691 0.86 MAPT (0.60) MAPTPOLBHSD17B10MEN1KMT2A
SCHEMBL1924720 0.86 MAPT (0.60) MAPTPOLBHSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1670801-B1 PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-06-08 EP disclosed
US-7514443-B2 Substituted pyrazolo[1,5-a]pyrimidines as inhibitors of metabotropic glutamate receptors HOFFMANN-LA ROCHE INC. (US) 2009-04-07 US disclosed
US-20080051421-A1 Pyrazolo-pyridine WICHMANN JUERGEN 2008-02-28 US disclosed
US-7329662-B2 Pyrazolo-pyridine HOFFMANN-LA ROCHE INC. (US) 2008-02-12 US disclosed
US-20050130992-A1 Pyrazolo-pyridine F. HOFFMANN-LA ROCHE AG (CH) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130992-A1 Pyrazolo-pyridine CHRM2, CHRM1, QDPR MAPT 1263/4885POLB 3144/4885HSD17B10 3505/4885
US-20080051421-A1 Pyrazolo-pyridine CHRM2, CHRM1, QDPR MAPT 1263/4885POLB 3144/4885HSD17B10 3505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.